UNSPSC 51142034: Xylazine

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H16N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2KFG9TP5V8, chemically known as 5,6-dihydro-2-(2,6-xylidino)-4h-1,3-thiazine but generally known as xylazine, which bears US NIH Compound Identifier 5707. European Medicines Agency schedules Xylazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00120MIG. The term XYLAZINE is an International Non-Proprietary Name.

UNSPSC 51142034 Xylazine is a Commodity code representing pharmaceutical products procured by state and local health agencies, though recent activity under this specific code shows limited direct alignment with xylazine procurement itself. The source opportunities instead reflect broader state and local pharmaceutical purchasing: Seminole County, Florida is acquiring naloxone (an opioid antagonist and harm-reduction product) and drug deactivation systems through IFB 60459723LAS, while the Texas Health and Human Services Commission has issued an RFI to explore direct-to-manufacturer prescription fulfillment models, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is soliciting generic multi-source pharmaceuticals and OTC products through a formal RFP. State and local buyers using this code span county health departments, state health agencies, and multi-state purchasing cooperatives. The work involves sourcing pharmaceutical inventory—both specialty products like naloxone tied to opioid response initiatives and broader generic pharmaceuticals—for distribution through authorized wholesaler networks or direct procurement channels. Vendors must typically maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, workers' compensation and general liability insurance, and E-Verify eligibility confirmation.

Recent solicitation activity concentrates in Florida and Texas, with multi-state cooperative procurement through Minnesota. The Seminole County IFB released July 10, 2023 with a July 26, 2023 response deadline seeks 1,900 units of naloxone and 800 drug deactivation systems annually on a two-year contract with one-year renewal option, requiring quarterly delivery to Sanford, Florida and including all shipping costs in bids. MMCAP's RFP, posted January 20, 2026 with a March 26, 2026 response deadline, targets generic pharmaceuticals and OTC products for multi-state distribution through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing structure, and 5 percent each on administrative compliance and EDI capability. The Texas HHS Commission's RFI issued April 3, 2026 represents exploratory procurement seeking vendor capability data on direct-to-manufacturer prescription programs before a formal RFP release. None of the opportunities name explicit set-aside designations for disadvantaged enterprises.